XENE Stock Forecast: Xenon Pharmaceuticals, Inc. Price Predictions for 2026-2027
The 18 Wall Street analysts covering Xenon Pharmaceuticals, Inc. hold a median 12-month price target of $72 — +93.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 41 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Xenon Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (87): The share price has been relatively steady.
Growth (28): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
XENE stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on XENE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +93.0% from it.
Of the 20 most recent actions, 1 moved their price target up and 8 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Nov 2026 | JP Morgan | Maintains | Overweight | $82 → $80 |
| 6 Oct 2026 | Guggenheim | Assumes | Buy | $73 |
| 18 Sept 2026 | Baird | Maintains | Outperform | $97 → $90 |
| 18 Sept 2026 | Deutsche Bank | Downgrade | Hold | $90 → $46 |
| 18 Sept 2026 | Needham | Maintains | Buy | $78 → $60 |
| 18 Sept 2026 | RBC Capital | Maintains | Outperform | $81 → $70 |
| 18 Sept 2026 | Wedbush | Maintains | Outperform | $71 → $55 |
| 18 Sept 2026 | Wells Fargo | Maintains | Overweight | $69 → $64 |
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | $82 → $81 |
| 27 May 2026 | JP Morgan | Maintains | Overweight | $80 → $82 |
| 12 May 2026 | JP Morgan | Maintains | Overweight | — |
| 8 May 2026 | Needham | Maintains | Buy | — |
| 8 May 2026 | RBC Capital | Maintains | Outperform | — |
| 16 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 10 Mar 2026 | Deutsche Bank | Maintains | Buy | — |
| 10 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 10 Mar 2026 | Wells Fargo | Maintains | Overweight | — |
| 9 Mar 2026 | Baird | Maintains | Outperform | — |
| 9 Mar 2026 | Needham | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for XENE.
This page is one stock. Monday covers all of them.
XENE appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
XENE vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Xenon Pharmaceuticals, Inc. returned −8.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
XENE analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 492.2×
- Price / book
- 3.2×
- EV / EBITDA
- —
Cheaper than 1% of US stocks
Cheaper than 28% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −50.3%
- Return on assets
- −32.2%
- Dividend yield
- —
Higher than 22% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Xenon Pharmaceuticals, Inc. has a market value of $3.7B and an enterprise value of $2.7B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$409.2M.
Diluted earnings per share, trailing twelve months: −$4.74.
Free cash flow in the twelve months to 30 June 2026: −$338.5M.
Xenon Pharmaceuticals, Inc. employs 358 people.
Data provided by Twelve Data
XENE and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at XENE’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Xenon Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about XENE
What is the XENE stock price forecast for 2026-2027?
The 18 Wall Street analysts covering Xenon Pharmaceuticals, Inc. have a median 12-month price target of $72, with estimates ranging from $46 to $90. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is XENE stock a buy right now?
Of the 18 analysts covering Xenon Pharmaceuticals, Inc., 17 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xenon Pharmaceuticals, Inc. 41 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank XENE?
As at 21 Nov 2026, Xenon Pharmaceuticals, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (87 of 100).
Will XENE stock go up?
No one can know that. What the data says: the median 12-month target from 18 analysts implies +93.0% from the last close, and Ticker Nerd's factor model ranks Xenon Pharmaceuticals, Inc. 41 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the XENE stock forecast for 2030?
No analyst covering Xenon Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XENE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $46 to $90 over the next 12 months.
How has XENE stock performed over the past year?
Xenon Pharmaceuticals, Inc. returned -8.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Xenon Pharmaceuticals, Inc. do?
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company that develops therapies for neurological and psychiatric disorders. Xenon Pharmaceuticals Inc. concentrates on ion channel science and small-molecule drug discovery, with a pipeline centered on treatments for epilepsy and other central nervous system conditions.
About Xenon Pharmaceuticals, Inc.
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company that develops therapies for neurological and psychiatric disorders. Xenon Pharmaceuticals Inc. concentrates on ion channel science and small-molecule drug discovery, with a pipeline centered on treatments for epilepsy and other central nervous system conditions. Its current programs include late-stage and early-stage candidates aimed at focal seizures, primary generalized tonic-clonic seizures, major depressive disorder, bipolar depression, and pain. The company operates as a single reportable segment focused on discovering, developing, and delivering therapeutics for patients with high unmet medical needs. Headquartered in Burnaby, British Columbia, Xenon Pharmaceuticals Inc. has an operating presence in North America and collaborates with clinical and research partners to advance its development programs.
CEO Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. · 358 employees · Canada · https://www.xenon-pharma.com